Status:
COMPLETED
Treatment of Schizophrenia With an Omega-3 Fatty Acid (EPA) and Antioxidants
Lead Sponsor:
University Hospital, Aker
Collaborating Sponsors:
Diakonhjemmet Hospital
Stanley Medical Research Institute
Conditions:
Schizophrenia
Schizophreniform Disorders
Eligibility:
All Genders
18-40 years
Phase:
PHASE2
PHASE3
Brief Summary
The purpose of this trial is to study the effect of adding the omega-3 fatty acid EPA and/or Vitamins E + C to antipsychotic drugs in younger patients with schizophrenia and related psychoses.
Detailed Description
Objective: Study the effect of adding Ethyl-EPA and/or Vitamins E + C to antipsychotic drugs in younger patients with schizophrenia and related psychoses. Methods and material: * Design: Multicentr...
Eligibility Criteria
Inclusion
- Patients with schizophrenia, schizophreniform disorder or schizoaffective disorder (DSM-IV)
- Admitted to a psychiatric hospital/department within the previous twenty-one days before screening
- Less than fifteen years, in retrospect, since first psychotic symptoms (DSM-IV 295, criteria A,1-4)
- Age 18-40 years
- Speaks fluently a Scandinavian language
- A written informed consent must be obtained before any trial-related activities
Exclusion
- A diagnosis of substance dependence (DSM-IV)
- Known allergy to study medication
- Currently taking warfarin or having anamnestic indicators of impaired haemostasis (profuse bleeding, except epistaxis)
Key Trial Info
Start Date :
September 1 2001
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2004
Estimated Enrollment :
99 Patients enrolled
Trial Details
Trial ID
NCT00419146
Start Date
September 1 2001
End Date
April 1 2004
Last Update
January 4 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Aker University Hospital
Oslo, Norway, 0320